Design: Randomised, open-label phase 3 trial, planned interim analysis
Population: 709 children with newly diagnosed high-risk B-cell ALL, after consolidation
Primary outcome: Event-free survival
Effect: 4-year EFS 83.0% vs 70.3%; HR 0.51 (95% CI 0.35–0.73)

In the AIEOP-BFM ALL 2017 trial, 709 children with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia were randomised after consolidation to two cycles of blinatumomab, a CD19-directed bispecific T-cell engager, or two cycles of conventional chemotherapy.

At a planned interim analysis (median follow-up 2.9 years), estimated four-year event-free survival was 83.0% with blinatumomab and 70.3% with chemotherapy (HR 0.51, 95% CI 0.35 to 0.73). Treatment-related infection fell from 69.4% to 23.9%. Life-threatening adverse events occurred in 0.5% vs 4.7%. Neurotoxic events were more common with blinatumomab (12.0% vs 3.2%); grade 2 or higher cytokine release syndrome was 1.1%.

This is one of the clearest cases of a targeted therapy being more effective than the chemotherapy it replaces, with fewer infections and life-threatening events but more neurotoxicity. Most clinicians will meet these children afterwards, in general practice or paediatrics, and need to know that immunotherapy is now part of front-line treatment.

Blinatumomab replacing two chemotherapy cycles improved four-year event-free survival in high-risk B-cell ALL.
Infection risk fell sharply; neurotoxicity (tremor, seizures, confusion) rose and needs recognising.
A child with fever or new neurological symptoms during blinatumomab should be discussed urgently with the treating oncology team.
Access in India depends on cost and centre; the result sets a standard, not yet universal practice.

Why it matters

It shows targeted therapy can replace toxic chemotherapy rather than just add to it.

The statistics, in plain English

A hazard ratio of 0.51 means about half the rate of relapse, resistance, second cancer or death. Interim analyses stopped early for benefit can overstate the effect; longer follow-up will refine the number. The 83% vs 70% are estimates at four years projected from a median 2.9 years of follow-up.